Abstract
Antibodies mediate humoral immune responses and play key roles in the defense of viral infection by the recognition, neutralization, and elimination of viruses from the circulation. For the prevention of respiratory syncytial virus (RSV) infection, the pooled human plasma has been harvested and successfully developed as a prophylactic polyclonal RSV hyperimmune globulin, RespiGam (RSV-IGIV; MedImmune, Gaithersburg, MD). The success of RSV-IGIV validated the immunoprophylaxis approach for RSV prevention and led to the development of Synagis (palivizumab; MedImmune, Gaithersburg, MD), a humanized monoclonal antibody (mAb) that binds to the RSV F protein. Palivizumab is a potent anti-RSV mAb that is about 50-fold more potent than RSV-IGIV, and since obtaining regulatory approval in 1998 it has been used extensively to help prevent severe RSV disease in high-risk infants and children. However, a very small number of patients receiving the drug do not appear to be adequately protected. To further improve protection against RSV, we have applied a directed evolution approach to enhance the binding of palivizumab to F protein by assessment of both on and off rates. These efforts have yielded a more potent second-generation mAb, motavizumab, which is currently under study in phase III clinical trials. Most recently, a third generation mAb, Numax-YTE, has been generated with the intent to extend the half-life in serum of the mAb in humans. The aim of this review is to evidence the pharmacokinetic and pharmacodynamic characteristics of these drugs and to evaluate their efficacy.
Keywords: Prevention, palivuzumab, motavizumab, VRS
Current Respiratory Medicine Reviews
Title: Prevention of Respiratory Syncytial Virus: A Review
Volume: 5 Issue: 1
Author(s): Emilio Palumbo
Affiliation:
Keywords: Prevention, palivuzumab, motavizumab, VRS
Abstract: Antibodies mediate humoral immune responses and play key roles in the defense of viral infection by the recognition, neutralization, and elimination of viruses from the circulation. For the prevention of respiratory syncytial virus (RSV) infection, the pooled human plasma has been harvested and successfully developed as a prophylactic polyclonal RSV hyperimmune globulin, RespiGam (RSV-IGIV; MedImmune, Gaithersburg, MD). The success of RSV-IGIV validated the immunoprophylaxis approach for RSV prevention and led to the development of Synagis (palivizumab; MedImmune, Gaithersburg, MD), a humanized monoclonal antibody (mAb) that binds to the RSV F protein. Palivizumab is a potent anti-RSV mAb that is about 50-fold more potent than RSV-IGIV, and since obtaining regulatory approval in 1998 it has been used extensively to help prevent severe RSV disease in high-risk infants and children. However, a very small number of patients receiving the drug do not appear to be adequately protected. To further improve protection against RSV, we have applied a directed evolution approach to enhance the binding of palivizumab to F protein by assessment of both on and off rates. These efforts have yielded a more potent second-generation mAb, motavizumab, which is currently under study in phase III clinical trials. Most recently, a third generation mAb, Numax-YTE, has been generated with the intent to extend the half-life in serum of the mAb in humans. The aim of this review is to evidence the pharmacokinetic and pharmacodynamic characteristics of these drugs and to evaluate their efficacy.
Export Options
About this article
Cite this article as:
Palumbo Emilio, Prevention of Respiratory Syncytial Virus: A Review, Current Respiratory Medicine Reviews 2009; 5 (1) . https://dx.doi.org/10.2174/157339809787354001
DOI https://dx.doi.org/10.2174/157339809787354001 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Chronic obstructive pulmonary disease (COPD) from childhood to adulthood: from the past to the future
Chronic obstructive pulmonary disease (COPD) is one of the three leading causes of death worldwide, with a major prevalence in low- and middle-income countries, resulting in a high social and economic cost. It is a heterogeneous respiratory disease, treatable and preventable, that causes persistent and often progressive airway obstruction in ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroprotective Effects of Quercetin: From Chemistry to Medicine
CNS & Neurological Disorders - Drug Targets Propitious Profile of Peppery Piperine
Current Molecular Pharmacology Immunomodulatory Activity of Garlic
Current Immunology Reviews (Discontinued) The Role of PDE5-Inhibitors in Cardiopulmonary Disorders: From Basic Evidence to Clinical Development
Current Medicinal Chemistry Lysophosphatidic Acid and Renal Fibrosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Alternative Host Models for Testing Anti-Protozoal or Antifungal Compounds and Fungal Infection
Current Topics in Medicinal Chemistry Pro Atrial Natriuretic Peptide (1-30) and 6-keto PGF<sub>1α</sub> Activity Affects Na<sup>+</sup> Homeostasis in Non-modulating Hypertension
Current Hypertension Reviews A Role of the Parasympathetic Nervous System in Cognitive Training
Current Alzheimer Research Multiple Lipid-lowering Treatment in Pediatric Patients with Hyperlipidemia
Medicinal Chemistry Insights into Structure-Activity Relationships and CNS Therapeutic Applications of NR2B Selective Antagonists
Current Medicinal Chemistry Gender Differences in Autonomic Control of the Cardiovascular System
Current Pharmaceutical Design Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Novel Concepts in the Management of Angina in Coronary Artery Disease
Current Pharmaceutical Design Electrochemical MIP-Sensors for Drugs
Current Medicinal Chemistry Muscle Development and Regeneration in Normal and Pathological Conditions: Learning from Drosophila
Current Pharmaceutical Design Diagnosis of Cardiovascular Diseases Using Retinal Images Through Vessel Segmentation Graph
Current Medical Imaging The Anti Inflammatory Effects of High Density Lipoproteins
Current Medicinal Chemistry Mitochondrial and Nuclear Genes of Mitochondrial Components in Cancer
Current Genomics The TOLL-like / Type-I Interferon Pathways as Emerging Therapeutic Targets for Autoimmune Diseases
Drug Design Reviews - Online (Discontinued) Phytochemical Genistein in the Regulation of Vascular Function: New Insights
Current Medicinal Chemistry